Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $17.11 Average Price Target from Brokerages

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have earned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $17.11.

A number of brokerages recently issued reports on ATEC. Barclays increased their price objective on Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 19th. Needham & Company LLC reiterated a “buy” rating and set a $13.00 price target on shares of Alphatec in a research report on Thursday, October 31st. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Alphatec in a research report on Thursday, October 31st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ATEC. XTX Topco Ltd purchased a new stake in Alphatec in the 3rd quarter worth approximately $69,000. Net Worth Advisory Group bought a new position in Alphatec during the 3rd quarter valued at approximately $76,000. Van ECK Associates Corp raised its position in shares of Alphatec by 57.0% in the 3rd quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock worth $99,000 after purchasing an additional 6,998 shares during the last quarter. Tempus Wealth Planning LLC purchased a new position in Alphatec in the third quarter worth about $107,000. Finally, Atria Investments Inc lifted its position in Alphatec by 8.0% in the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock valued at $109,000 after acquiring an additional 1,460 shares in the last quarter. Institutional investors own 66.35% of the company’s stock.

Alphatec Price Performance

Shares of NASDAQ ATEC opened at $9.37 on Friday. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. Alphatec has a fifty-two week low of $4.88 and a fifty-two week high of $17.34. The stock has a market cap of $1.33 billion, a PE ratio of -7.32 and a beta of 1.38. The stock has a fifty day moving average of $9.13 and a 200-day moving average of $8.03.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.